{
    "Trade/Device Name(s)": [
        "Alinity c Benzodiazepines Reagent Kit"
    ],
    "Submitter Information": "Microgenics Corporation Thermo Fisher Scientific",
    "510(k) Number": "K243498",
    "Predicate Device Reference 510(k) Number(s)": [
        "K173963"
    ],
    "Regulatory Class": "",
    "Product Code(s)": [
        "JXM"
    ],
    "Summary Letter Date": "November 11, 2024",
    "Summary Letter Received Date": "",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3170"
    ],
    "Regulation Name(s)": [
        "Enzyme Immunoassay, Benzodiazepine"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzodiazepines",
        "benzodiazepine metabolites",
        "oxazepam (calibrator)"
    ],
    "Specimen Type(s)": [
        "Human urine"
    ],
    "Specimen Container(s)": [
        "Plastic container",
        "Glass container"
    ],
    "Instrument(s)/Platform(s)": [
        "Alinity c Analyzer System"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Alinity c Benzodiazepines Reagent Kit for qualitative and semiquantitative detection of benzodiazepines and metabolites in human urine using the Alinity c analyzer.",
    "Indications for Use Summary": "Qualitative and/or semiquantitative determination of benzodiazepines and their metabolites in human urine at 200 ng/mL cutoff on Alinity c analyzer, as a rapid screening test to aid in detecting benzodiazepine use or abuse, for laboratory use by trained professionals.",
    "fda_folder": "Toxicology"
}